We are live on ! Find out more
XBIT icon

XBiotech
XBIT

37 hedge funds and large institutions have $4.68M invested in XBiotech in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,154% more call options, than puts

Call options by funds: $163K | Put options by funds: $13K

0.99% less ownership

Funds ownership: 7.53% → 6.54% (-0.99%)

10% less funds holding

Funds holding: 41 → 37 (-4)

15% less capital invested

Capital invested by funds: $5.48M → $4.68M (-$802K)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

Holders
37
Holders Change
-4
Holders Change %
-9.76%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
8
Reduced
12
Closed
8
Calls
$163K
Puts
$13K
Net Calls
+$150K
Net Calls Change
+$108K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$54.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$23.9K
3
BCM
Bridgeway Capital Management
Texas
+$21.5K
4
BlackRock
BlackRock
New York
+$10.8K
5
Morgan Stanley
Morgan Stanley
New York
+$5.16K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$446K
2
Millennium Management
Millennium Management
New York
-$72.3K
3
Squarepoint
Squarepoint
New York
-$55.1K
4
Goldman Sachs
Goldman Sachs
New York
-$40.2K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$35.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$11.8K -$63 -26 -0.5%
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$2.18K – – –
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$2K +$2.43K +1,003 +539%
ME
29
McIlrath & Eck
Washington
$1.77K – – –
Jones Financial Companies
30
Jones Financial Companies
Missouri
$840 – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$218 -$2.5K -1,032 -91%
SS
32
SBI Securities
Japan
$87 +$87 +36 +3,600%
LFG
33
Larson Financial Group
Missouri
$49 – – –
AAP
34
Arax Advisory Partners
Colorado
$35 +$36 +15 New
Carson Wealth (CWM LLC)
35
Carson Wealth (CWM LLC)
Nebraska
$31 -$24 -10 -43%
CIAM
36
Caitong International Asset Management
Hong Kong
$26 +$27 +11 New
Optiver Holding
37
Optiver Holding
Netherlands
$19 – – –
Ameriprise
38
Ameriprise
Minnesota
– -$446K -186,796 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$40.2K -16,831 Closed
Two Sigma Advisers
40
Two Sigma Advisers
New York
– -$39K -16,300 Closed
PAP
41
Persistent Asset Partners
Hong Kong
– -$32.4K -13,565 Closed
TSS
42
Two Sigma Securities
New York
– -$24.8K -10,378 Closed
Fidelity Investments
43
Fidelity Investments
Massachusetts
– -$1.08K -450 Closed
Simplex Trading
44
Simplex Trading
Illinois
– -$162 -67 Closed
Barclays
45
Barclays
United Kingdom
– -$2 -1 Closed
1
2

XBIT Hedge Fund Activity: Q1 2026 in Review

37 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2026, worth a combined $4.68M — down 15% from $5.48M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of XBIT and 6 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $54.3K. The largest seller was Ameriprise, exiting entirely with an estimated $446K sold.

  • 37 institutional investors held XBiotech (XBIT) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $4.68M of XBiotech stock for Q1 2026, down 15% quarter-over-quarter.
  • 6 funds opened new XBiotech positions in Q1 2026 and 8 closed out, a net change of -2 holders.
  • The largest XBiotech buyer in Q1 2026 was Renaissance Technologies, an estimated $54.3K added.
  • The largest XBiotech seller in Q1 2026 was Ameriprise, an estimated $446K sold.

Based on aggregated 13F filings for Q1 2026.